$Eli Lilly(LLY)$ 's experimental pill orforglipron showed promising results in diabetes and weight loss trials, causing the stock to surge 16%. Despite market volatility from tariffs, this dip presents a strategic buying opportunity. Investors can capitalize on the stock's long-term growth potential.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Another one